National Cancer Institute; Notice of Closed Meetings, 38192-38193 [2016-13930]
Download as PDF
<![CDATA[
38192
Federal Register / Vol. 81, No. 113 / Monday, June 13, 2016 / Notices
assigned OMB control number 0990–
0275, which expires on 08/31/2016.
Prior to submitting the ICR to OMB, OS
seeks comments from the public
regarding the burden estimate, below, or
any other aspect of the ICR.
DATES: Comments on the ICR must be
received on or before August 12, 2016.
ADDRESSES: Submit your comments to
Information.CollectionClearance@
hhs.gov or by calling (202) 690–6162.
FOR FURTHER INFORMATION CONTACT:
Information Collection Clearance staff,
Information.CollectionClearance@
hhs.gov or (202) 690–6162.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
document identifier HHS–OS–0990–
0275–60D for reference.
Information Collection Request Title:
Performance Data System (PDS) (OMB
No. 0990–0275).
Abstract: This request for clearance is
to revise data collection activities and
extend by three (3) years a currently
approved collection using the OMB
approved Performance Data System
(PDS) (OMB No. 0990–0275), the tool
used by the Office of Minority Health
(OMH) to collect program management
and performance data for all OMHfunded projects. The revised data
collection activities pertain only to
current questions about grantee use of
social media. The modified social media
questions in PDS will be more
applicable to OMH grantees, more easily
understood, and collect more accurate
quantitative metrics. Grantee data
collection via the UDS (original data
collection system) was first approved by
OMB on June 7, 2004 (OMB No. 0990–
275). OMB approval was also received
for modifications to the UDS (August
23, 2007), which upgraded the data
collection tool from the UDS to the PDS
(August 31, 2010). A 3-year extension
without change of the approved PDS
collection was approved August 1, 2013.
Clearance is due to expire on August 31,
2016.
Need and Proposed Use of the
Information: The clearance is needed to
continue data collection using the PDS,
a system that enables OMH to comply
with Federal reporting requirements and
monitor and evaluate performance by
enabling the efficient collection of
performance-oriented data tied to OMHwide performance reporting needs. The
ability to monitor and evaluate
performance in this manner, and to
work towards continuous program
improvement are basic functions that
OMH must be able to accomplish in
order to carry out its mandate with the
most effective and appropriate use of
resources. The revision of the social
media questions is necessary because
social media platforms, such as
Facebook, Twitter, and blogs, are
becoming increasingly utilized by
grantees for their usability, free access,
and ability to reach a larger audience.
The revised questions will lead to
increased data collection completeness
and quality.
Likely Respondents: Respondents for
this data collection include the project
directors for OMH-funded projects and/
or the date entry persons for each OMHfunded project. Affected public includes
non-profit institutions, State, Local, or
Tribal Governments.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions, to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information, to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information, and to
transmit or otherwise disclose the
information.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden
per response
(in hours)
Total burden
hours
PDS ..................................................................................................................
100
4
1.5
600
Total ..........................................................................................................
100
4
1.5
600
srobinson on DSK5SPTVN1PROD with NOTICES
OS specifically requests comments on
(1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Terry S. Clark,
Asst Information Collection Clearance
Officer.
[FR Doc. 2016–13833 Filed 6–10–16; 8:45 am]
BILLING CODE 4150–29–P
VerDate Sep<11>2014
20:48 Jun 10, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Diagnostics, Prognostics and Detection.
Date: June 15, 2016.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
4W032/034, Rockville, MD 20850,
(Telephone Conference Call).
Contact Person: Gerard Lacourciere, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W248, Rockville, MD 20892–9750,
240–276–5457, gerard.lacourciere@
mail.nih.gov.
E:\FR\FM\13JNN1.SGM
13JNN1
Federal Register / Vol. 81, No. 113 / Monday, June 13, 2016 / Notices
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Software
for Measuring Environmental Effects on
Cancer.
Date: June 30, 2016.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
4W030 Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Gerard Lacourciere, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, 9609 Medical Center Drive,
Room 7W248, Rockville, MD 20892–9750,
240–276–5457, gerard.lacourciere@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: June 8, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–13930 Filed 6–10–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Announcement of Requirements and
Registration for ‘‘$100,000 for Start a
SUD Startup’’ Challenge
The National Institute on
Drug Abuse (NIDA), one of the
components of the National Institutes of
Health (NIH), announces the ‘‘$100,000
for Start a SUD Startup’’ Challenge. The
Challenge goal is to support research
ideas that would further an
understanding of neurobiology as it
relates to Substance Use Disorders
(SUD) and that are intended to be the
basis for the development of a new and
potentially successful start-up. NIDA
hopes that participation in the contest
will enable scientists to test the
hypothesis that their research idea can
be fostered into a biotech startup, and
that eventually any newly created
startups will contribute to the pool of
innovative small business companies
that can successfully compete for
NIDA’s Small Business Innovation
srobinson on DSK5SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:48 Jun 10, 2016
Jkt 238001
Research (SBIR) and Small Business
Technology Transfer (STTR) funding.
Each Challenge winner will receive
$10,000. The Challenge total purse is up
to $100,000.
DATES: The Challenge begins June 13,
2016.
Submission Period: June 13, 2016 to
September 16, 2016, 11:59 p.m., ET.
Judging Period: September 19, 2016 to
October 21, 2016.
Winners Announced: October 24,
2016.
FOR FURTHER INFORMATION CONTACT: Irina
Sazonova, Ph.D., M.Sc., Health Scientist
Administrator, Office of Translational
Initiatives and Program Innovations
(OTIPI), NIDA Challenge Administrator,
National Institute on Drug Abuse
(NIDA), 6001 Executive Blvd. Room
4206, MSC 9555 Bethesda, MD 20892–
9555. Phone: (301) 827–9564, Email:
irina.sazonova@nih.gov.
SUPPLEMENTARY INFORMATION: The
Institute’s Statutory Authority to
Conduct the Challenge. NIDA is
conducting this Challenge under the
America Creating Opportunities to
Meaningfully Promote Excellence in
Technology, Education, and Science
(COMPETES) Reauthorization Act of
2010, 15 U.S.C. 3719. The general
purpose of NIDA is to conduct and
support biomedical and behavioral
research, health-services research,
research training, and healthinformation dissemination with respect
to the prevention of drug abuse and the
treatment of drug abusers. This
Challenge is consistent with and
advances the mission of NIDA as
described in 42 U.S.C. 285o in that it
supports new and potential biotech
start-ups in the development of research
ideas that would further an
understanding of neurobiology as it
relates to SUD.
Subject of Challenge. NIDA is excited
to announce the first competition for
biomedical scientists with the goal to
support research ideas that would
further an understanding of
neurobiology as it relates to SUD and
that are intended to be the basis for the
development of a new and potentially
successful start-up. NIDA hopes that
participation in the contest will enable
scientists to test whether their research
ideas can be fostered into a biotech
startup. In 2016, NIDA will award up to
$100,000 in prizes to up to 10 winners
of the contest, $10,000 each.
Are you a biomedical scientist who
believes that he/she has a research idea
for a biotech start-up? This Challenge is
unique because NIDA intends to fund
the ‘‘would be’’ startup Founders much
earlier than most investors, incubators,
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
38193
or traditional modes of research funding
(e.g. small business grants).
What does it take to participate in the
Challenge? The team or an individual
must have a research idea that could
further the understanding of SUD and is
intended to be the basis of the
development of a new and potentially
successful startup. The research ‘‘idea’’
is the product that your future startup
will offer. Here, the term startup
‘‘product’’ is used in its broadest
definition. Product is any source of
value for the people who become
customers. Services, subscriptions,
software as a service (SaaS), physical/
tangible products, aggregations, etc.
could all provide value and thus be
considered startup products. The
startup product could be the result of
novel scientific discoveries, repurposing
an existing technology for a new use,
extending a research observation into a
different area, devising a new business
model or distribution/delivery channel
that unlocks value currently concealed,
or simply bringing a product or service
to previously underserved set of
customers. The Founder (the teams or
an individual) must demonstrate
through the Submission the passion,
drive, discipline, ability to work
collaboratively and willingness to push
forward under conditions of extreme
business uncertainty.
The winners of this Challenge are
encouraged to use the prize funds to
develop a minimum viable proof (MVP)
as quickly as possible and to obtain
customer feedback to discover if MVP
meets the customer needs. If the product
prototype is successfully validated,
winners are encouraged to create or
further advance their biotech startup no
later than 6 months after the prize is
awarded. Post Challenge, as with all
other NIH grant applicants, NIDA staff
will provide dedicated assistance and
guidance about the NIH grant
submission process, including
submissions for the SBIR/STTR grants.
The research idea must be broad
enough to address multiple conditions,
diseases, or indications consistent with
SUD or be specific for prevention and
treatments of SUD. For example, if your
idea can only work for cancer or
diabetes, entering this Challenge is not
appropriate. However, if the plan is to
test an idea for a research tool that
would further an understanding of
neurobiology or epigenetics relevant to
SUD to progress faster and with greater
fidelity, entering this Challenge is
appropriate.
Rules for Participating in the
Challenge. The Challenge is open to any
Founder 18 years of age or older. No
prior startup experience is necessary. A
E:\FR\FM\13JNN1.SGM
13JNN1
]]>Agencies
[Federal Register Volume 81, Number 113 (Monday, June 13, 2016)]
[Notices]
[Pages 38192-38193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13930]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Diagnostics, Prognostics and Detection.
Date: June 15, 2016.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 4W032/034, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Gerard Lacourciere, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, 9609 Medical
Center Drive, Room 7W248, Rockville, MD 20892-9750, 240-276-5457,
gerard.lacourciere@mail.nih.gov.
[[Page 38193]]
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Software for Measuring Environmental Effects on Cancer.
Date: June 30, 2016.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 4W030 Rockville, MD 20850, (Telephone Conference
Call).
Contact Person: Gerard Lacourciere, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, 9609 Medical
Center Drive, Room 7W248, Rockville, MD 20892-9750, 240-276-5457,
gerard.lacourciere@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: June 8, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-13930 Filed 6-10-16; 8:45 am]
BILLING CODE 4140-01-P
